VyBio closes RMB 100M+ Series B round led by Qiming Venture Partners

Recently, Hangzhou-based innovative drug developer VyBio Therapeutics announced the completion of a Series B funding round totaling nearly 100 million RMB. This round was exclusively invested by Qiming Venture Partners, with continued support from existing shareholders including TF Capital, Hangzhou State-owned Capital Group, and Runzhang Venture Capital. The proceeds will accelerate clinical development of the company's multiple pipeline assets.

Founded in 2021, VyBio Therapeutics is headquartered in Hangzhou with a global vision, focusing on developing first-in-class and best-in-class Category 1 innovative drugs with worldwide intellectual property. The company's pipeline targets oncology and chronic disease therapies, with multiple candidates having entered Phase I and Phase II clinical trials.

VyBio Therapeutics has assembled a world-class team of pharmaceutical innovation experts and management talent. The core founding team includes graduates from prestigious institutions such as Tsinghua University, University of California Los Angeles, State University of New York, The University of Hong Kong, and West China Medical Center, Sichuan University.

This exceptional talent pool serves as the core driver for the company's innovative drug development. VyBio has achieved significant progress with multiple innovative drug candidates targeting hypertension and various solid tumors. Clinical-stage assets include the highly selective aldosterone synthase inhibitor VB19055, along with small molecule targeted therapies TFX05, TFX06, and VB15. The preclinical pipeline encompasses small molecules and small nucleic acids targeting oncology, hypertension, hyperlipidemia, and diabetes.